Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors.

Mihalak KB, Carroll FI, Luetje CW.

Mol Pharmacol. 2006 Sep;70(3):801-5. Epub 2006 Jun 9.

2.

Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation.

Rollema H, Coe JW, Chambers LK, Hurst RS, Stahl SM, Williams KE.

Trends Pharmacol Sci. 2007 Jul;28(7):316-25. Epub 2007 Jun 18. Review.

PMID:
17573127
3.

The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: a review.

Crunelle CL, Miller ML, Booij J, van den Brink W.

Eur Neuropsychopharmacol. 2010 Feb;20(2):69-79. doi: 10.1016/j.euroneuro.2009.11.001. Epub 2009 Dec 3. Review.

PMID:
19959340
4.

Varenicline: progress in smoking cessation treatment.

Glover ED, Rath JM.

Expert Opin Pharmacother. 2007 Aug;8(11):1757-67. Review.

PMID:
17685891
5.
6.

Varenicline: for smoking cessation.

Rao J, Shankar PK.

Kathmandu Univ Med J (KUMJ). 2009 Apr-Jun;7(26):162-4. Review.

PMID:
20071853
7.
8.

[Varenicline--a new chance for smokers?].

Goniewicz ML, Koszowski B, Czogała J, Sobczak A.

Przegl Lek. 2007;64(10):899-902. Review. Polish.

PMID:
18409337
9.

Varenicline: a first-line treatment option for smoking cessation.

Garrison GD, Dugan SE.

Clin Ther. 2009 Mar;31(3):463-91. doi: 10.1016/j.clinthera.2009.03.021. Review.

PMID:
19393839
10.

Efficacy and safety of varenicline for smoking cessation.

Hays JT, Ebbert JO, Sood A.

Am J Med. 2008 Apr;121(4 Suppl 1):S32-42. doi: 10.1016/j.amjmed.2008.01.017. Review.

PMID:
18342165
11.

Varenicline and its role in smoking cessation.

Kapoor S.

Prev Cardiol. 2008 Summer;11(3):168-71. Review.

12.

Nicotinic receptor antagonists as treatments for nicotine abuse.

Crooks PA, Bardo MT, Dwoskin LP.

Adv Pharmacol. 2014;69:513-51. doi: 10.1016/B978-0-12-420118-7.00013-5. Review.

13.

α4β2* neuronal nicotinic receptor ligands (agonist, partial agonist and positive allosteric modulators) as therapeutic prospects for pain.

Nirogi R, Goura V, Abraham R, Jayarajan P.

Eur J Pharmacol. 2013 Jul 15;712(1-3):22-9. doi: 10.1016/j.ejphar.2013.04.021. Epub 2013 May 7. Review.

PMID:
23660369
14.

Varenicline and neuronal nicotinic acetylcholine receptors: a new approach to the treatment of co-occurring alcohol and nicotine addiction?

Nocente R, Vitali M, Balducci G, Enea D, Kranzler HR, Ceccanti M.

Am J Addict. 2013 Sep-Oct;22(5):453-9. doi: 10.1111/j.1521-0391.2013.12037.x. Epub 2013 May 15. Review.

PMID:
23952890
15.

[Nicotine and neurologic diseases--even a noxious substance may possess beneficial properties].

Kaakkola S, Tuominen R.

Duodecim. 2013;129(16):1654-60. Review. Finnish.

PMID:
24069634
16.

Neuronal nicotinic acetylcholine receptors as pharmacotherapeutic targets for the treatment of alcohol use disorders.

Chatterjee S, Bartlett SE.

CNS Neurol Disord Drug Targets. 2010 Mar;9(1):60-76. Review.

17.

Improvement of restless legs syndrome by varenicline as antismoking treatment.

Romigi A, Vitrani G.

J Clin Sleep Med. 2013 Oct 15;9(10):1089-90. doi: 10.5664/jcsm.3092. Review.

18.

Varenicline.

Kassem MG, Al Hossaini AM.

Profiles Drug Subst Excip Relat Methodol. 2012;37:389-411. doi: 10.1016/B978-0-12-397220-0.00010-6. Epub 2012 Mar 19. Review. No abstract available.

PMID:
22469324

Supplemental Content

Support Center